Tuberculosis, Multidrug-Resistant Clinical Trial
— StakeOfficial title:
Preventing Acquired Resistance: Strengthen TB Treatment by Adding Amikacin in the First Treatment Week of Multidrug-resistant Tuberculosis (Stake) Amendment to Study Protocol: "All-oral Shorter Treatment Regimen for Multidrug- and Rifampicin-resistant Tuberculosis (MDR/RR-TB): Evaluating Its Effectiveness, Safety and Impact on the Quality of Life of Patients in Rwanda" (ShORRT)
Acquired drug-resistance is a major challenge for tuberculosis (TB) care programs. The 2020 WHO guidelines recommends replacing second-line injectables by bedaquiline in rifampicin-resistant TB (RR-TB) treatment regimens. However, recent reports show too high rates of acquired bedaquiline resistance. This may be explained by the delayed onset of action of bedaquiline. The investigators will study whether high-dose amikacin (a second-line injectable), administered during the first week of RR-TB treatment, is safe in 20 patients treated for RR-TB in Rwanda. If safe, further studies will assess whether adding amikacin in the first treatment week protect against acquired bedaquiline resistance. This study is embedded in an ongoing "Master study" of the ShORRT (short oral RR-TB) treatment regimen in Rwanda, a before/after study, with a retrospective cohort (before; the previously recommended second-line injectable-containing RR-TB regimen) and a prospective cohort (after: the newly recommended ShORRT regimen).
Status | Recruiting |
Enrollment | 20 |
Est. completion date | February 2026 |
Est. primary completion date | March 2024 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 19 Years to 64 Years |
Eligibility | Inclusion Criteria: - Enrolled in the Master SHORRT study - Able and willing to provide written informed consent for the present substudy "Stake" Exclusion Criteria: - Any audiometry abnormality (grade 1 or higher) on baseline audiometry - History of kidney disease or baseline creatinine clearance below or equal to 60ml/min - Pregnant or breastfeeding women - History of previous injectable based tuberculosis treatment (including with streptomycin) - < 18 years and > 65 years old - Patient on NSAID or on diuretics Master ShORRT study Inclusion criteria: - Is willing and able to give informed consent to be enrolled in the research project and for follow-up - Has bacteriologically or molecularly confirmed TB with evidence of resistance to at least rifampicin Exclusion criteria: - Is unable to take oral medication; - Must take any medications contraindicated with the medicines in the MDR/RR-TB regimen; - Has a known allergy to any of the drugs in the MDR/RR-TB regimen; - Has a QTcF interval of = 500 msec; at baseline that does not correct with medical management. |
Country | Name | City | State |
---|---|---|---|
Rwanda | Kabutare hospital | Kabutare |
Lead Sponsor | Collaborator |
---|---|
Rwanda Biomedical Centre | Institute of Tropical Medicine, World Health Organization |
Rwanda,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | grade 3-4 AE likely or definitively related to amikacin | Assess whether less than 14% of patients treated with the amikacin-strengthened regimen will experience a grade 3-4 adverse event likely or definitively related to the use of amikacin | After 2 weeks of treatment | |
Secondary | turnaround times | Assess the turnaround times to inform the feasibility of doing the tests proposed in this study for the assessment of the response to the use of two doses of amikacin | at the end of treatment week 2 (+/- 3 d) | |
Secondary | testing coverage | Assess the testing coverage (proportion of patients with a result for each of the tests) to inform the feasibility of doing the tests proposed in this study for the assessment of the response to the use of two doses of amikacin | at the end of treatment week 2 (+/- 3 d) | |
Secondary | AE likely or definitely related to amikacin | Describe the occurrence of adverse events that are considered as likely or definitely related to the use of amikacin | at the end of treatment week 2 (+/- 3 d) | |
Secondary | amikacin concentration | Describe the amikacin concentration stratified by values for different treatment response markers : Colony forming units on semi-quantitative culture | during the first two treatment weeks | |
Secondary | amikacin concentration | Describe the amikacin concentration stratified by values for different treatment response markers : molecular bacterial load | during the first two treatment weeks | |
Secondary | amikacin concentration | Describe the amikacin concentration stratified by values for different treatment response markers : thin-layer agar semi-quantitative culture | during the first two treatment weeks | |
Secondary | amikacin concentration | Describe the amikacin concentration stratified by values for different treatment response markers: RNA Synthesis ratio | during the first two treatment weeks | |
Secondary | amikacin concentration | Describe the amikacin concentration stratified by values for different treatment response markers : time to culture positivity on liquid culture | during the first two treatment weeks | |
Secondary | post-injection pain | Describe post-injection pain on a 0-10 pain scale (The Wong-Baker FACES pain rating scale) (15) | at 0, 15 minutes, 30 minutes and 60 minutes after the injection of amikacin with lidocaine on day 1 and 4, as well as the next morning | |
Secondary | all AE, relationship with TB drugs | Describe all AE, by their grade, and their relationship with TB drugs | at the end of the ShORRT study, approximately 23 months after the treatment | |
Secondary | treatment outcomes | Describe treatment outcomes, using the following effectiveness endpoints:
Month of stable (without reversion) culture conversion End-of-treatment outcomes (treatment failure, death during treatment, LTFU during treatment, cure, treatment completion) Treatment outcomes at 12 months post-treatment (end-of treatment outcome corrected for relapse) Acquired resistance to bedaquiline, fluoroquinolone, amikacin through target deep sequencing on paired baseline and failure sputa |
at the end of treatment | |
Secondary | post-treatment outcomes | Describe post-treatment outcomes, using the following effectiveness endpoints:
Month of stable (without reversion) culture conversion End-of-treatment outcomes (treatment failure, death during treatment, LTFU during treatment, cure, treatment completion) Treatment outcomes at 12 months post-treatment (end-of treatment outcome corrected for relapse) Acquired resistance to bedaquiline, fluoroquinolone, amikacin through target deep sequencing on paired baseline and failure sputa |
after post-treatment follow-up (part of ShORRT analysis) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT05871489 -
Strengthening Evidence on Optimal Multidrug-resistant Tuberculosis Treatment Regimens
|
||
Active, not recruiting |
NCT02715271 -
Study of TB Lesions Obtained in Therapeutical Surgery
|
||
Active, not recruiting |
NCT04179500 -
A Trial to Evaluate the Male Reproductive Safety of Pretomanid in Adult Male Participants With Drug Resistant Pulmonary Tuberculosis Volunteers
|
Phase 2 | |
Completed |
NCT03086486 -
Various Doses and Durations of Linezolid Plus Bedaquiline & Pretomanid in Participants With Drug Resistant Tuberculosis
|
Phase 3 | |
Completed |
NCT01201941 -
Operational Assessment of Laboratory Information System for MDR-TB in Lima, Peru
|
N/A | |
Not yet recruiting |
NCT06441006 -
Program for Rifampicin-Resistant Disease With Stratified Medicine for Tuberculosis
|
Phase 3 | |
Completed |
NCT03303963 -
DIAgnostics for Multidrug Resistant Tuberculosis in Africa
|
||
Completed |
NCT02413931 -
Nosocomial Transmission of MDR-TB in Bucharest, Romania
|
||
Recruiting |
NCT05306223 -
A Study of an Oral Short-course Regimen Including Bedaquiline for the Treatment of Participants With Multidrug-resistant Tuberculosis in China
|
Phase 4 | |
Completed |
NCT02573350 -
A Trial to Evaluate Safety, Tolerability, and Efficacy of Orally Administered OPC-67683
|
Phase 2 | |
Completed |
NCT02597621 -
Biomarkers for Therapy Response in Drug-resistant Tuberculosis
|
||
Recruiting |
NCT03828201 -
Efficacy and Tolerability of Bedaquiline, Delamanid, Levofloxacin, Linezolid, and Clofazimine to Treat MDR-TB
|
Phase 2 | |
Recruiting |
NCT01212003 -
Training Protocol on the Natural History of Tuberculosis
|
||
Terminated |
NCT03237182 -
The Individualized M(X) Drug-resistant TB Treatment Strategy Study
|
Phase 4 | |
Completed |
NCT03338621 -
Trial to Evaluate the Efficacy, Safety and Tolerability of BPaMZ in Drug-Sensitive (DS-TB) Adult Patients and Drug-Resistant (DR-TB) Adult Patients
|
Phase 2/Phase 3 | |
Not yet recruiting |
NCT05007795 -
Test to Treat TB: Impact of Sputum Sequencing-guided Individualised Therapy on Outcomes in Drug-resistant Tuberculosis
|
N/A | |
Completed |
NCT03728725 -
Xpert MTB/XDR Clinical Evaluation Trial
|
||
Completed |
NCT02589782 -
Pragmatic Clinical Trial for a More Effective Concise and Less Toxic MDR-TB Treatment Regimen(s)
|
Phase 2/Phase 3 | |
Recruiting |
NCT02619994 -
Treatment Shortening of MDR-TB Using Existing and New Drugs
|
Phase 2 | |
Completed |
NCT01918397 -
Efficacy and Safety of Levofloxacin for the Treatment of MDR-TB
|
Phase 2 |